Chugai Applies For Additional Indication For Avastin For Recurrent Glioblastoma
This article was originally published in PharmAsia News
Chugai Pharmaceuticals announced Sept. 19 that it has filed an application for an additional indication for an intravenous infusion of anti-cancer drug Avastin (bevacizumab) for recurrent glioblastoma.
You may also be interested in...
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.
The Japan-headquartered drugmaker says there is a need for affordable oral treatment options on top of currently available lipid-lowering therapies and the two drugs it licensed from Esperion can meet that need.
CSL Behring is backing the US biotech SAB Biotherapeutics in developing polyclonal antibodies in cattle for their efficacy against the pandemic virus, adding a second strand to the research efforts of the blood products specialty company.